{"university":{"openalex_id":"I161716053","name":"China Pharmaceutical University"},"topic":"mitochondrial-replacement","total_matching":2,"offset":0,"next_offset":null,"records":[{"doi":"https://doi.org/10.21203/rs.3.rs-2327478/v1","title":"Suppression of mitochondrial heterogeneity via engineered mitochondria for reversion of mitochondrial disease-related phenotypes","source_url":"https://doi.org/10.21203/rs.3.rs-2327478/v1","source_name":"Research Square","cited_by_count":0,"is_open_access":true,"openalex_work_id":"W4311210515","publication_date":"2022-12-12","publication_year":2022,"university_research_work_topics":[{"topic_slug":"mitochondrial-replacement"}]},{"doi":"https://doi.org/10.1016/j.apsb.2024.08.007","title":"Nanoengineered mitochondria enable ocular mitochondrial disease therapy via the replacement of dysfunctional mitochondria","source_url":"https://doi.org/10.1016/j.apsb.2024.08.007","source_name":"Acta Pharmaceutica Sinica B","cited_by_count":18,"is_open_access":true,"openalex_work_id":"W4401539251","publication_date":"2024-08-13","publication_year":2024,"university_research_work_topics":[{"topic_slug":"mitochondrial-replacement"}]}],"automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}